A Phase II Study of Oxaliplatin in Association With 5FU and Folinic Acid in the Treatment of Subjects With Non-Surgical or Advanced Metastatic Gastric Cancer

Inclusion Criteria: * Histologically proven gastric or gastroesophagic junction adenocarcinoma * Measurable disease at least in a unidimensional manner. If a unique metastasis constitutes the only disease symptom, histological confirmation will be required * Metastatic or locally non-surgical primary gastric cancer * Recurrent gastric cancer after local and/or systemic treatment with a post-surgical period of at least 4 weeks, a post-adjuvant chemotherapy period or a neo-adjuvant chemo-radiotherapy of at least 6 months * Serum bilirubin\< 2 mg/dl * Serum creatinine \< or =to 2 times normal superior limit * Absolute neutrophil count \> or =to 2000/dl * Platelet count \> or =to 100000/dl * Hemoglobin \> or =to 10 g/dl * AST/ALT \< or =to 2.5 times normal superior institutional limit * Alkaline phosphatase \< or =to 5 times the normal superior institutional limit * Age \> 18 years * Performance Status ECOG 0-2 * Written informed consent signed and dated Exclusion Criteria: * Symptomatic sensory peripheral neuropathy * Uncontrolled concomitant disease.(e.g. severe diabetes mellitus, arterial hypertension) * Any other malignancy diagnosed within 5 years previous to the gastric cancer, with the exception of " in situ " cervix carcinoma or non-melanoma skin cancer * Concomitant anti-tumoral treatment * Cerebral metastases * Unstable heart disease, even though under treatment * Myocardial infarction within the last 6 months * Pregnancy or nursing (or women in reproductive life without adequate contraception) * Significant neurological or psychiatric disorders